Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. by Lambregts, D.M. et al.
  
 
Diffusion-weighted MRI for selection of complete
responders after chemoradiation for locally advanced
rectal cancer: a multicenter study.
Citation for published version (APA):
Lambregts, D. M., Vandecaveye, V., Barbaro, B., Bakers, F. C., Lambrecht, M., Maas, M., ... Beets Tan,
R. G. (2011). Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally
advanced rectal cancer: a multicenter study. Annals of Surgical Oncology, 18(8), 2224-2231.
https://doi.org/10.1245/s10434-011-1607-5
Document status and date:
Published: 01/08/2011
DOI:
10.1245/s10434-011-1607-5
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
ORIGINAL ARTICLE – COLORECTAL CANCER
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ABSTRACT
Purpose. In 10–24% of patients with rectal cancer who are
treated with neoadjuvant chemoradiation, no residual
tumor is found after surgery (ypT0). When accurately
selected, these complete responders might be considered
for less invasive treatments instead of standard surgery. So
far, no imaging method has proven reliable. This study was
designed to assess the accuracy of diffusion-weighted MRI
(DWI) in addition to standard rectal MRI for selection of
complete responders after chemoradiation.
Methods. A total of 120 patients with locally advanced
rectal cancer from three university hospitals underwent
chemoradiation followed by a restaging MRI (1.5T), con-
sisting of standard T2W-MRI and DWI (b0-1000). Three
independent readers first scored the standard MRI only for
the likelihood of a complete response using a 5-point
confidence score, after which the DWI images were added
and the scoring was repeated. Histology (ypT0 vs. ypT1-4)
was the standard reference. Diagnostic performance for
selection of complete responders and interobserver agree-
ment were compared for the two readings.
Results. Twenty-five of 120 patients had a complete
response (ypT0). Areas under the ROC-curve for the three
readers improved from 0.76, 0.68, and 0.58, using only
standard MRI, to 0.8, 0.8, and 0.78 after addition of DWI
(P = 0.39, 0.02, and 0.002). Sensitivity for selection of
complete responders ranged from 0–40% on standard MRI
versus 52–64% after addition of DWI. Specificity was
equally high (89–98%) for both reading sessions. Interob-
server agreement improved from j 0.2–0.32 on standard
MRI to 0.51–0.55 after addition of DWI.
Conclusions. Addition of DWI to standard rectal MRI
improves the selection of complete responders after che-
moradiation.
The introduction of preoperative, rather than postoper-
ative, adjuvant chemoradiation therapy (CRT) has led to a
reduction in local recurrence rates and has become standard
of care for patients with locally advanced rectal cancer.1 In
10–24% of patients, no residual tumor is found at histology
after surgery.2 These complete responders are known to
have a very good prognosis, in terms of overall and dis-
ease-free survival.2 A complete response also raises the
hotly debated question of whether surgery is still necessary
for these patients, especially because total mesorectal
excision (TME) may have associated morbidity and
even mortality and has the potential risk of a permanent
colostomy. Recently, a more conservative treatment is
advocated in patients who show a good or complete
response to neoadjuvant treatment. In 2006, Habr-Gama
et al. presented the long-term results of a prospective trial
that investigated a ‘‘wait-and-see’’ policy in a carefully
selected group of patients with clinical and radiological
evidence of a complete response after neoadjuvant CRT.
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Results at 5-year follow-up were favorable for the non-
surgical group, with an overall and disease-free survival of
93% and 85%, respectively.3 To safely omit surgery, it is
essential to select accurately the right candidates, i.e., the
true complete responders. This selection is mainly per-
formed using digital examination, endoscopy, and biopsy,
but these methods are not infallible. The role of imaging
for restaging after CRT has been the subject of several
studies and all suggest that neither MRI nor endorectal
ultrasound or 18F-fluorodeoxyglucose-positron emission
tomography (FDG-PET) are sufficiently accurate for
identifying the true complete responders with positive
predictive values ranging from 17–50%.4–9 The use of
these modalities for selection of patients would conse-
quently put them at risk for undertreatment.
Diffusion-weighted MRI (DWI) is a functional MR
imaging technique that uses differences in the extracellular
movement of water protons to discriminate between tissues
of varying cellularity. In tissues with normal cellularity,
water protons can diffuse relatively freely, which results in
a loss of signal on DWI. Conversely, in tissues with
increased cellularity (tumor), the diffusion of water is
restricted, resulting in remaining high signal on DWI. In
many reports, DWI has shown promise for identification of
malignant tumors, and recent studies on rectal cancer have
indicated that DWI also may be useful for response eval-
uation after chemoradiation treatment.8,10–15 In 2009, Kim
et al. showed in a study of 40 patients that DWI in addition
to standard MRI significantly improved the performance of
radiologists to select complete responders compared with
standard MRI only.8
The purpose of our study was to evaluate the accuracy of
DWI in addition to a standard restaging MRI for selection
of complete responders after chemoradiation for locally
advanced rectal cancer in a larger and multicenter study
setting.
METHODS AND MATERIALS
Patients
This study retrospectively evaluated 120 consecutive
patients who were treated for locally advanced rectal cancer
in three university hospitals between 2005 and 2009. Due to
the retrospective nature of the study, informed consent was
not required. Ninety-three patients were men and 27 were
women. Median age was 67 (range 22–89) years. Inclusion
criteria consisted of (1) biopsy-proven rectal cancer, (2)
locally advanced disease as determined on primary staging
MRI (T3-4 tumor, tumor involvement of the mesorectal
fascia, and/or positive nodal status), (3) preoperative treat-
ment consisting of a long course of neoadjuvant chemo-
radiation treatment, and (4) availability of posttreatment MR
imaging, including DWI. Exclusion criteria consisted of (1)
nonresectable disease and (2) insufficient MR image quality
(e.g., due to metal or motion artefacts). All patients under-
went a long course of preoperative chemoradiation,
consisting of capecitabine and/or oxaliplatin, combined with
50.4–55 Gy of radiation. After a 5–10-week time interval, all
patients underwent a second, restaging MRI, including DWI,
for response evaluation. Patients were then referred for fur-
ther treatment.
MR Imaging
In each participating center, imaging was performed at
1.5T using a phased array body coil. The MR protocol con-
sisted of standard T2-weighted fast spin echo sequences (as
described in literature) in three orthogonal directions: sag-
ittal, axial, and coronal with an in plane resolution ranging
from 0.42–2.56 mm2 and a slice thickness of 4–5 mm.16 An
additional diffusion-weighted echo planar imaging sequence
was acquired with b0 as the lowest and b1000 s/mm2 as the
highest b-factor, an in plane resolution of 7.8–9.6 mm2 and a
slice thickness of 4–5 mm, as described in previous reports
from the participating centers.17–19
Image Evaluation
All images were independently analysed by three read-
ers, who were blinded to all clinical information, other
imaging results, and histopathology. Reader 1 (RGHB) was
a gastrointestinal (GI) radiologist who was highly spe-
cialized with 13 years of experience in reading pelvic MRI.
Reader 2 (FCHB) was a GI radiologist with 3 years of
experience in reading pelvic MRI. Reader 3 (VV) was a GI
radiologist with 2 years pelvic MRI expertise and 5 years
of experience in reading DWI images in head and neck,
abdominal cancer, and lymphoma. The three readers first
evaluated the standard postchemoradiation (restaging) MR
images and scored the likelihood of a complete response
of the primary tumor using a confidence level score
(0 = definitely residual tumor, 1 = probably residual
tumor, 2 = possibly residual tumor/possibly complete
response, 3 = probably complete response, 4 = definitely
complete response). The pre-CRT images were at the
readers’ disposal to identify the primary tumor, which is
just like the evaluation process performed in daily clinical
practice. Subsequently, the confidence level-based scoring
of the restaging MRI was repeated after addition of the
b1000 DWI images.
Imaging Criteria
On standard MRI, a normalized rectal wall without any
detectable wall thickening was considered a definite
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criterion for a complete response (Fig. 1). A solid residual
mass with intermediate signal intensity on T2-weighted
MRI was considered a definite criterion for residual tumor
(Fig. 2). Hypointense signal intensity changes indicated
fibrosis, in which case undetermined scores were assigned
(Fig. 3).18 On the diffusion images, residual high-signal
intensity on the location of the primary tumor was con-
sidered a criterion for residual tumor, whereas the absence
of increased signal on DWI was indicative of a complete
response (Fig. 3). The readers assigned a confidence level 2
score (equivocal score) when they were not able to dif-
ferentiate between a complete response or residual tumor.
Reference Standard
Histopathologic evaluation of the surgical resection
specimen, according to the TNM staging system, served as
the reference standard. The tumor regression grade (TRG)
was evaluated according to the method of Mandard.20 The
response of the primary tumor to chemoradiation was gra-
ded as follows: ‘‘pathologic complete response’’ (= ypT0/
TRG 1, no residual tumor cells) or ‘‘residual tumor’’
(= ypT1-4 / TRG 2-5, varying from limited tumor cells to a
solid residual tumor mass). Eight patients did not undergo
surgery, due to strong clinical evidence of a complete
response (repeated negative sigmoidoscopy and biopsies
after CRT). For these eight patients, a local and distant
recurrence-free follow-up period of [24 months was con-
sidered a surrogate endpoint for a complete response.
Statistical Analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS, version 16.0, Inc.,
Chicago, IL). Receiver operator characteristics (ROC)
curve analyses were performed to evaluate the diagnostic
performance of (1) standard MRI only and (2) standard
MRI ? DWI for identification of a complete response.
Corresponding areas under the ROC curve (AUC), sensi-
tivities, specificities, positive predictive values (PPV), and
negative predictive values (NPV) with 95% confidence
intervals (CI) were calculated. For these analyses, it had
been decided at the start of the study to dichotomize the
confidence level scores between 2 (possibly residual tumor/
possibly complete response) and 3 (probably complete
response). Differences in diagnostic performance between
standard MRI only and the combination of standard
MRI ? DWI were analyzed by comparing the ROC curves
FIG. 1 Standard T2-weighted images
of a female patient with a tumor (T) in
the mid-rectum, before (a) and after
(b) preoperative chemoradiation
therapy. After chemoradiation, the
tumor has completely disappeared and a
normalized rectal wall can be visualized
(arrowheads). This feature was
considered strongly predictive for a
complete tumor response
FIG. 2 Standard T2-weighted images
of a male patient with a tumor (T) in the
rectum, before (a) and after
(b) preoperative chemoradiation
therapy. After chemoradiation, a solid
residual tumor mass is still visualized
(arrow). This feature was considered
strongly predictive for the presence of
residual tumor
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according to the method described by DeLong et al.21
P values \ 0.05 were considered statistically significant.
Weighted kappa values with quadratic kappa weighting
(0–0.2 poor, 0.21–0.4 fair, 0.41–0.6 moderate, 0.61–0.8
good and 0.81–1 excellent agreement) were calculated to
evaluate interobserver variability.22
RESULTS
Patient and Treatment Characteristics
A total of 79 patients underwent low anterior resection,
25 had abdominoperineal resection, 4 had more extended
surgery, and 4 had local excision (transanal endoscopic
microsurgery). At histology, 17 patients had ypT0, 11 had
ypT1, 25 had ypT2, 55 had ypT3 and 4 had ypT4 status.
Ten patients had mucinous type adenocarcinoma. The
median time interval between the restaging MRI and sur-
gery was 15 (range 0–61) days. The eight patients who did
not undergo surgery had a median local and distant
recurrence-free follow-up of 42.5 (range 26–73) months;
these patients were therefore considered complete
responders. All together, 25 patients had a complete
response and 95 had residual tumor. Of the patients with
residual tumor, 63 were yN0, 22 were yN1, and 10 were
yN2 status. Of the patients with a complete tumor response,
23 were yN0, 1 was yN1, and 1 was yN2 status. There were
no significant differences in patient characteristics, gender,
or age distribution between the separate centers.
Diagnostic Performance for Selection of Complete
Responders
ROC curves for the selection of complete responders are
displayed in Fig. 4. Corresponding accuracy figures and
AUCs with 95% confidence intervals are provided in
Table 1. For the highly expert reader 1, AUC improved
from 0.76 for standard MRI to 0.8 for standard
MRI ? DWI (P = 0.39). For the less experienced reader
2, AUC improved from 0.68 on standard MRI to 0.8 after
addition of DWI (P = 0.02). For reader 3, AUC improved
from 0.58 on standard MRI to 0.78 after addition of DWI
(P = 0.002).
Number of Equivocal (Confidence Level 2) Scores
When using only standard MRI without DWI, readers 1,
2, and 3 assigned a confidence level score of 2 (possibly
residual tumor/possibly complete response) to 31, 7, and 41
patients, respectively. After addition of DWI, the number
of equivocal scores decreased to 2, 4, and 2 for the three
readers, respectively. This resulted in a reduced number of
false negatives for prediction of a complete tumor
response, ranging from 9–12 for the three readers on
standard MRI ? DWI compared with 15–25 on standard
MRI only. The number of false positives remained
unchanged and ranged from 2–8 on standard MRI and from
3–10 after addition of DWI.
FIG. 3 Standard T2-weighted images of two patients with a tumor
(T) in the rectum before (a, d) and after chemoradiation treatment (b,
e). In both cases, the tumor bed has become fibrotic after chemora-
diation (arrowheads), which makes it difficult to discriminate
between residual tumor and a complete response. In the upper
patient, there is still a clear high signal intensity area on DWI (arrow
in c), which was confirmed to be a ypT2 residual tumor at histology.
In the lower patient, no high signal is shown on DWI (f) and a
complete tumor response (ypT0) was confirmed at histology
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Interobserver Agreement
Kappa values for the interobserver agreement between
the three readers are displayed in Table 2. Interobserver
agreement improved from fair agreement (j 0.2–0.32) on
standard MRI to moderate agreement (j 0.51–0.55) after
addition of DWI.
DISCUSSION
The findings of this study indicate that the diagnostic
performance for predicting a pathologic complete tumor
response after chemoradiation improved for the combina-
tion of standard MRI ? DWI (AUC 0.78–0.8) compared
with standard MRI only (AUC 0.58–0.76). With the addi-
tion of DWI, sensitivity for identification of a complete
response improved by 16–52% for the three readers.
Standard MRI
Standard MRI + DWI
Reference Line
AUC 0.76
AUC 0.80
1.0
1.0
0.8
0.6
0.4
0.2
0.0
1-Specificity
Sensitivity Reader 1
0.2 0.4 0.6 0.8
Standard MRI
Standard MRI + DWI
Reference Line
AUC 0.68
AUC 0.80*
1.0
1.0
0.8
0.6
0.4
0.2
0.0
1-Specificity
Sensitivity Reader 2
0.2 0.4 0.6 0.8
Standard MRI
Standard MRI + DWI
Reference Line
AUC 0.58
AUC 0.78*
1.0
1.0
0.8
0.6
0.4
0.2
0.0
1-Specificity
Sensitivity Reader 3
0.2 0.4 0.6 0.8
FIG. 4 Receiver operator characteristics curves and areas under the
curve (AUC) of the three readers for identification of a complete
tumor response after CRT using only standard MRI and standard
MRI ? DWI, respectively. Diagnostic performance improved signif-
icantly (*) for reader 2 (P = 0.02) and reader 3 (P = 0.002). For
reader 1, there was no significant improvement (P = 0.39)
TABLE 1 Diagnostic performance for the prediction of a complete response (ypT0)
Standard MRI only Standard MRI ? DWI
R1 R2 R3 R1 R2 R3
Sensitivity 40 (10/25) 28 (7/25) 0 (0/25) 56 (14/25) 64 (16/25) 52 (13/25)
95% CI 26–53 16–40 0–0 41–67 48–77 39–60
Specificity 92 (87/95) 93 (88/95) 98 (93/95) 94 (89/95) 89 (85/95) 97 (92/95)
95% CI 88–95 89–96 98–99 90–97 85–93 93–99
PPV 56 (10/18) 50 (7/14) 0 (0/2) 70 (14/20) 62 (16/26) 81 (13/16)
95% CI 36–73 28–71 0–0 52–84 46–74 60–93
NPV 85 (87/102) 83 (88/106) 79 (93/118) 89 (89/100) 90 (85/94) 88 (92/104)
95% CI 82–88 80–86 79–80 85–92 86–94 85–90
AUC 0.76 0.68 0.58 0.80 0.80 0.78
95% CI 0.65–0.86 0.56–0.8 0.47–0.69 0.69–0.91 0.7–0.91 0.67–0.9
R1 reader 1, GI radiologist with 13 years experience in pelvic MRI; R2 reader 2, GI radiologist with 3 years experience in pelvic MRI; R3 reader
3, GI radiologist with 2 years experience in pelvic MRI and 5 years experience in reading DWI; PPV positive predictive value; NPV negative
predictive value; AUC area under the ROC curve; CI confidence interval
Numbers are percentages; absolute numbers are given in parentheses
TABLE 2 Interobserver agreement between the three readers
Observers Standard MRI only (j) Standard MRI ? DWI (j)
R1 and R2 0.32 0.55
R1 and R3 0.31 0.52
R2 and R3 0.2 0.51
R1 reader 1, GI radiologist with 13 years experience in pelvic MRI;
R2 reader 2, GI radiologist with 3 years experience in pelvic MRI; R3
reader 3, GI radiologist with 2 years experience in pelvic MRI and
5 years experience in reading DWI
Kappa values are weighted kappa’s with quadratic kappa weighting
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Moreover, it resulted in a substantial reduction in the
number of equivocal scores and an improved interobserver
agreement.
Of interest is the improved sensitivity for the combina-
tion of MRI ? DWI; i.e., it resulted in less overestimation
of tumor in patients with a complete tumor response. This is
mainly because on the restaging MRI without DWI many
interpretation difficulties were observed when the primary
tumor bed had become fibrotic as a result of the radiation
treatment. In these cases, it is difficult to differentiate small
areas of residual tumor from mere fibrosis and readers tend
to overestimate the presence of tumor (Fig. 3).23–26
Apparently, this is where the functional information from
DWI proves beneficial. Areas of fibrosis typically have a
low cellular density, which results in low signal intensity on
high b-value (b1000) diffusion images.27 Conversely,
residual tumor areas have a relatively high cellular density
and show high signal on DWI, which stands out within the
low signal of the surrounding tissue/fibrosis. This is the
reason why small areas of residual tumor are better depicted
on DWI.8,27 Nevertheless, interpretation errors were still
observed with DWI resulting in a suboptimal sensitivity of
52–64%. When the signal of the normal rectal wall is not
fully suppressed on DWI, which often occurs when the
rectal wall is collapsed, high signal at the location of the
initial tumor area may erroneously be interpreted as residual
tumor, resulting in overstaging errors. In addition, some
imaging artifacts may occur on DWI, particularly around
air-tissue interfaces. It is relevant to recognize these short-
comings of DWI and initiate teaching courses in which
radiologists will be trained in the interpretation of DWI and
will become familiar with its pitfalls. Specificity for MRI
and DWI is [90%, indicating that the residual tumors are
accurately detected and the risk for undertreatment will be
\10%. Although DWI allows detection of even small
(2–5 mm) tumor volumes, the challenge will remain the
detection of microscopically small clusters of residual
tumor cells, which are difficult to detect—even at histol-
ogy—and are currently beyond the detection level of any
available imaging modality, including DWI.
The addition of DWI improved the performance of all
readers, albeit that this benefit was not significant for
reader 1. His extensive experience of 13 years in inter-
preting rectal cancer MRI may explain why reader 1 was
already more accurate with the use of only standard MRI
(AUC 0.76). This exceptionally high level of expertise
does not reflect common daily practice. Our study, how-
ever, clearly shows that for radiologists in general centers
with expertise levels like the other two readers, DWI can
really be of value. Furthermore, all readers showed a sig-
nificant reduction in equivocal (confidence level 2) scores
after addition of DWI, indicating that it raised their con-
fidence in the discrimination between complete responders
and residual tumor. This also explains the better interob-
server agreement between the readers after addition of
DWI.
So far, the largest body of evidence for response eval-
uation exists for 18FDG-PET. Changes in FDG uptake, in
particular early (±2 weeks) after onset of treatment, have
proven useful for prediction of response.4,28,29 PET is,
however, less reliable in identifying the complete tumor
responders after completion of chemoradiation: up to 55%
of the residual tumors are overlooked and patients are
erroneously interpreted as complete responders.5,6,28 In a
recent study by Janssen et al., only one of six complete
responders as identified on FDG-PET corresponded with a
true complete response at histology.4 When using FDG-
PET for treatment planning, the main risk would be an
undertreatment of these patients. In our DWI-MRI study,
the presence of residual tumor was underestimated in only
\10% of the cases, indicating that—compared to PET—
there is a considerably smaller risk for undertreatment.
To the best of our knowledge, this is the largest and only
multicenter study to investigate the value of DWI for
identifying complete tumor responders after CRT for rectal
cancer. It confirms previous findings of a smaller, single-
center study by Kim et al.8 Previous studies also have
shown promise for quantitative DWI measurements of the
‘‘apparent diffusion coefficient’’ (ADC) (performed before,
during, and/or after chemoradiation treatment) to predict
the degree of response to therapy.8,10–15,17,30,31 In our
study, we only focussed on qualitative, visual evaluation of
DWI and did not quantitatively measure ADC. This is a
more convenient approach, because a visual analysis is
more practical and less time-consuming for a busy radiol-
ogy practice. Furthermore, ADC values are dependent on
technical variations among DWI sequences generated by
different MR equipment. ADC data from multiple centers
may be less suitable for pooled analysis. Visual evaluation
of DWI images is less subjected to technical variations, and
pooling of these data was feasible because all three par-
ticipating centers acquired a DWI sequence with equal
(b1000) diffusion weighting. Nevertheless, we acknowl-
edge that small variations between the participating centers
may have introduced some bias.
In the current study, we only focused on response
assessment of the primary tumor and not the lymph nodes.
The prevalence of a positive lymph node status in case of a
complete response of the primary tumor after CRT is very
low and was only 2 of 25 (8%) in the present study.
Nevertheless, to safely offer patients a wait-and-see policy
after CRT, we have to ensure that both the primary tumor
and all metastatic nodes have undergone a complete
regression (ypT0N0). Although standard MRI is known to
be inaccurate for the primary staging of rectal cancer
nodes,32,33 there is evidence that after chemoradiation,
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MRI performs considerably better. High NPVs ranging
from 81–100% have been reported, suggesting that the
ypN0 patients can already be accurately selected and the
addition of functional techniques, such as DWI, may not
even be necessary.7,19,23,34–36 Furthermore, the only study
to focus specifically on DWI for staging of rectal cancer
nodes after CRT already showed good results for standard
MRI only (NPV 94–95%) and reported no clear benefit
after addition of DWI (NPV 92–93%). The main role of
DWI for lymph node evaluation was that it improved the
number of detected nodes (both benign and malignant),
because nodes were more easily detected on DWI due to
their high signal intensity compared with the suppressed
background signal of surrounding tissues.19
Clinical Impact
A wait-and-see approach3 or local excision37 for patients
with a good response after chemoradiation is at present still
debatable. Initiating and performing large patient studies to
prove their efficiency is difficult, partly because clinicians
are not convinced that safe selection of the right patients
can be done. Therefore, one of the most important cor-
nerstones to make implementation of such minimally
invasive treatments possible is a precise selection of the
eligible patients. Our goal was to assess whether MR
imaging can be beneficial in this regard. Because of its
reported promise in cancer imaging, we particularly looked
at the potential of diffusion-weighted MRI. Moreover,
DWI is a noninvasive technique that does not require the
use of ionizing radiation or contrast agents and can easily
be added to any standard MRI protocol. Our results suggest
that, by combining morphological with functional imaging
information, MRI ? DWI can significantly improve sen-
sitivity for selection of complete responders. Furthermore,
specificity is [90%, which indicates that the risk for
underestimation of residual tumor can be brought to\10%.
As an adjunct to clinical tools (digital examination,
endoscopy, and biopsy), the combined use of MRI ? DWI
seems promising to enable a more precise selection of
patients eligible to undergo minimally invasive treatments.
The current results are obviously still premature for clinical
decision-making, but its promise warrants further large and
prospective patient studies.
In conclusion, this study shows that the addition of
diffusion-weighted imaging to a standard, restaging MRI
improves the performance and confidence of radiologists in
selecting the patients with a pathological complete tumor
response after chemoradiation for locally advanced rectal
cancer. The combination of MRI ? DWI could be of
additional value for the clinical assessment of these
patients.
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